首页> Diabetes research and clinical practice> Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes.

Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes.

导出 LinkOut

翻译打印收藏纠错

第一作者： Yoshimasa,Aso

第一单位： Department of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Tochigi, Japan. Electronic address: yaso@dokkyomed.ac.jp.

作者： Yoshimasa,Aso ^[1] ; Maiko,Fukushima ^[2] ; Masaaki,Sagara ^[3] ; Teruo,Jojima ^[3] ; Toshie,Iijima ^[3] ; Kunihiro,Suzuki ^[3] ; Atsushi,Momobayashi ^[2] ; Kikuo,Kasai ^[4] ; Toshihiko,Inukai ^[5]

作者单位： Department of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Tochigi, Japan. Electronic address: yaso@dokkyomed.ac.jp. ^[1] LSI Medience Corporation, Itabashi, Tokyo, Japan. ^[2] Department of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Tochigi, Japan. ^[3] Department of Medicine, Ishibashi General Hospital, Shimotsuke, Tochigi, Japan. ^[4] Department of Internal Medicine, Koshigaya Hospital, Dokkyo Medical University, Koshigaya, Saitama, Japan. ^[5]

关键词 CD4+ T cell DPP-4 inhibitor Regulatory T cell T-helper 17 cell